RhumbLine Advisers’s Aligos Therapeutics ALGS Stock Holding History

RhumbLine Advisers’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-681	Closed	-$37K	–	3093
2022 Q1	$37K	Buy	681 +155	+29%	+$12.4K	﹤0.01%	2986
2021 Q4	$156K	Sell	526 -18	-3%	-$6.57K	﹤0.01%	2883
2021 Q3	$211K	Buy	544 +42	+8%	+$16.6K	﹤0.01%	2896
2021 Q2	$256K	Buy	+502	New	+$320K	﹤0.01%	2850

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RhumbLine Advisers's ALGS Position: Q2 2022 in Review

RhumbLine Advisers sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 681 shares — an estimated $37K sold.

RhumbLine Advisers first reported a position in ALGS in Q2 2021 and held it in 4 quarters. The position peaked at $256K in Q2 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

RhumbLine Advisers reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
RhumbLine Advisers sold 681 Aligos Therapeutics shares in Q2 2022, an estimated $37K.
RhumbLine Advisers first reported a position in Aligos Therapeutics in Q2 2021 and held it in 4 quarters.
RhumbLine Advisers's Aligos Therapeutics position peaked at $256K in Q2 2021.
59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.